Global Pharmacovigilance Market: Snapshot
The global pharmacovigilance market is growing cumulatively as it is being driven by increase in awareness in the public health sector coupled with rise in preference for safe medicines. Globally, growing number of national pharmacovigilance centers is playing an imperative role to support the growth of the market in the next few years. Needless to mention, pharmacovigilance is witnessing numerous challenges to develop a better healthcare system. Unavailability of unskilled labor and information about drugs obtained via the web could be two high-impact restraints of the market. However, rigorous pharmacovigilance activities that could be made compulsory are expected to raise demand in the market. Such mandatory activities help to actively manage high-risk medicines.
Monitoring of Drug Safety Leads to Massive Growth in Phase III Clinical Trial
The world pharmacovigilance market could be segmented into preclinical studies, clinical trial phases I, II, III, and IV by phase of drug development. Phase IV a.k.a. post-marketing surveillance has contributed with its larger share in terms of revenue in the previous years. Safety worries relating to marketed products, growing necessity of designing systems to compare safety profiles of homologous medicinal products, and growth in public health awareness campaigns are few of the reasons which aid the growth of the segment.
Clinical trial phase III is predicted to set to rise at a higher CAGR because of escalating need for monitoring of drug safety. This phase emphasizes on drug safety and efficiency in diverse sub-groups, where the benefit-risk ratio is developed, scrutinized, and updated accordingly. In order to be more accurate on the part of drug safety, biopharmaceutical companies are focusing on creating advanced clinical trial phases.
Increased death rates because of adverse drug reactions (ADRs) and rise in patient fears regarding safety of medicinal products have propelled market growth of North America in the recent years. A report by Centers for Disease Control and Prevention (CDC) states that there are around 100,000 deaths caused by ADRs in the U.S. which are counted among the top ten leading causes of death in the country.
This post was originally published on Market Reports